Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HER2 ADC 7
- Development stage
- Preclinical
- Lead developer
- AbTis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
"anti-HER2 ADC 7" is an experimental, homogeneous antibody-drug conjugate (ADC) developed by AbTis Co., Ltd. for the treatment of HER2-expressing tumors, specifically glioblastoma multiforme (GBM). It consists of the anti-HER2 monoclonal antibody trastuzumab site-specifically conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) via a non-cleavable maleimidocaproyl (mc) linker, achieving a drug-to-antibody ratio (DAR) of 4.0. The conjugate is produced using AbTis's proprietary AbClick technology, which enables site-specific conjugation to the Fc region of native antibodies without genetic engineering. Research published in 2022 highlighted ADC 7 in studies comparing the blood-brain barrier (BBB) penetration and therapeutic efficacy of homogeneous versus heterogeneous ADCs, demonstrating that homogeneous conjugates with optimal payload loading provide superior brain tumor targeting and survival benefits in orthotopic models.
- Other names
- Trastuzumab-mcMMAE (DAR 4.0)AbClick-H-mcMMAE (DAR 4.0)
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on anti-HER2 ADC 7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HER2 ADC 7.